Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof inventions

20090270590 - Surface modified inorganic material and producing method thereof: A surface-modified inorganic material and a preparation method thereof. A surface-modified inorganic material is provided which is obtained by allowing an organosilane compound having allyl or an allyl derivative to react with an inorganic material, particularly solid silica or ITO glass, in the presence of an acid and an organic... Agent: D. Peter Hochberg Co. L.p.a.

20090270591 - Novel surface antigen: The invention provides a novel surface polypeptide from Neisseria meningitidis as well as nucleic acid and nucleic acid sequence homologues encoding this protein. Pharmaceutical compositions containing the polypeptide and nucleic acids of the invention are also disclosed as well as methods useful in the treatment, prevention and diagnosis of N.... Agent: Proskauer Rose LLP

20090270593 - Nucleic acid binding substance containing catalytic nucleation nanoparticles: A nucleic acid binding substance having an affinity for nucleic acid polymers. The nucleic acid binding substance is comprised of a nucleic acid binding element capable of specific binding to nucleic acid molecules and connected to a catalytic nucleation particle... Agent: Hiscock & Barclay, LLP

20090270592 - Purified tnfr preparations: Purified protein preparations comprising tumor necrosis factor are disclosed.... Agent: Legal Affairs Department Immunex Corporation

20090270594 - Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of allergies: The invention concerns the use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of allergies... Agent: Arent Fox LLP

20090270595 - Il-1 related polypeptides: The present invention is directed to novel polypeptides having homology to the IL-1-like family of proteins and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous... Agent: Genentech, Inc.

20090270596 - Chromatography purification of antibodies: Methods, kits and apparatuses for chromatography purification of antibodies are provided. In some embodiments, antibodies are purified by mixed mode chromatography that does not comprise hydroxyapatite (HT) or fluorapatite (FT). The mixed mode chromatography step is then followed by a HT/FT chromatography step.... Agent: Townsend And Townsend And Crew, LLP

20090270597 - Artificial antibody polypeptides: A fibronectin type III (Fn3) polypeptide monobody, a nucleic acid molecule encoding said monobody, and a variegated nucleic acid library encoding said monobody, are provided by the invention. Also provided are methods of preparing a Fn3 polypeptide monobody, and kits to perform said methods. Further provided is a method of... Agent: Viksnins Harris & Padys Pllp

20090270598 - Amphiphiles for protein solubilization and stabilization: The invention provides amphiphiles for manipulating membrane proteins. The amphiphiles can feature carbohydrate-derived hydrophilic groups and branchpoints in the hydrophilic moiety and/or in a lipophilic moiety. Such amphiphiles are useful as detergents for solubilization and stabilization of membrane proteins, including photosynthetic protein superassemblies obtained from bacterial membranes.... Agent: Schwegman Lundberg & Woessner/warf

20090270599 - In situ heat induced antigen recovery and staining method: An automated in situ heat induced antigen recovery and staining method and apparatus for treating a plurality of microscope slides. The process of heat induced antigen recovery and the process of staining the biological sample on the microscope slide are conducted in the same apparatus, wherein the microscope slides do... Agent: Dunlap Codding, P.C.

20090264616 - Cyclodipeptide synthetases and their use for synthesis of cyclo(leu-leu) cyclodipeptide: Isolated, natural or synthetic polynucleotides and the polypeptides encoded by said polynucleotides, that are involved in the synthesis of cyclodipeptides, the recombinant vectors comprising said polynucleotides or any substantially homologous polynucleotides, the host cell modified with said polynucleotides or said recombinant vectors and also methods for in vitro and in... Agent: The Nath Law Group

20090264617 - Method of producing fr901228: Depsipeptides and congeners thereof are disclosed having structure (I), wherein m, n, p, q, X, R1, R2 and R3 are as defined herein. These compounds, including FR901228, have activity as, for example, immunosuppressants, as well as for the prevention or treatment of patients suffering or at risk of suffering from... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20090264618 - Compounds with a branched linker: p

20090264619 - Metal-catalyzed copolymerization of imines and carbon monoxide as a route to synthesize polypeptides:

20090264620 - N-methylation of amino acids:

20090264621 - Lipid-assisted synthesis of polymer compounds and methods for their use: The invention herein disclosed provides for methods for the synthesis of polymers from monomers. In particular the method provides for the synthesis of polynucleotides from mononucleotides in the absence of catalytic enzymes. The invention is of particular use in the fields of molecular biology, structural biology, cell biology, molecular switches,... Agent: Bell & Associates

20090264624 - Human cytokine receptor: Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor16.”... Agent: Darby/zymogenetics, Inc.

20090264622 - Rhesus monkey nur77: The Macaca mulatta (rhesus monkey) Nur77 (rhNur77) nuclear receptor and the nucleic acid encoding the rhNur77 nuclear receptor are described. Further described are methods for identifying analytes that modulate expression or activity of the rhNur77 nuclear receptor. Analytes that affect Nur77 expression or activity may be used to treat or... Agent: Merck And Co., Inc

20090264623 - Sodium channel protein type iii alpha-subunit splice variant: The present invention is directed to a splice variant of a human sodium channel alpha subunit and methods and compositions for making and using the same.... Agent: Marshall, Gerstein & Borun LLP

20090264625 - Method for recombinant microorganism expression and isolation of collagen-like polypeptides: A composition comprising a purified collagen-like polypeptide suitable as a peptizer, said polypeptide comprising [Gly-X-Y]n repeats, wherein Gly stands for glycine, X and Y represent any amino acid and n is an integer and selected such that the length of the [Gly-X-Y]n repeat is at least 2.5 kDa and wherein... Agent: Nixon & Vanderhye, PC

20090264626 - Stabilization of the collagen triple helix by o-methylation of hydroxyproline residues: This invention relates to a collagen polypeptide comprising a tripeptide motif having the formula (ProYaaGly)n, where Yaa is an O-methylated amino acid residue and “n” is the number of motif repeats. Preferred O-methylated amino acid residues at the Yaa position include (2S,4R)-4-methoxyproline. Other suitable amino acid residues at that position... Agent: Quarles & Brady LLP

20090264627 - Enhancing the circulating half-life of antibody-based fusion proteins: Disclosed are compositions and methods for enhancing the circulating half-life of antibody-based fusion proteins. Disclosed methods and compositions rely on altering the amino acid sequence of the junction region between the antibody moiety and the fused protein moiety in an antibody-based fusion protein. An antibody-based fusion protein with an altered... Agent: K&l Gates LLP

20090264628 - Crystal structure of human urokinase plasminogen activator amino teminal fragment bound to its receptor: Urokinase-type plasminogen activator (uPA) binds its cellular receptor (uPAR) with high affinity, thus localizing the generation of plasmin from plasminogen on the surface of a variety of cells. Disclosed herein is the structure of suPAR (uPAR1-277) complexed with the amino terminal fragment (ATF) of uPA (uPA1-143) at a resolution of... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090264629 - Stabilized protein-containing formulations: Protein formulations containing a poloxamer as a surfactant, and methods for maintaining the biological activity in protein formulations without adding an antioxidant and for inhibiting the formation of foreign insoluble matters by adding a poloxamer as a surfactant.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090264631 - Immunoadsorption of anti-von willebrand factor cleaving protease antibodies: This invention relates to adsorbents and methods for highly selective removal of anti-von Willebrand Factor-cleaving protease antibodies (“anti-vWF-cp-abs”) from human plasma using human von Willebrand Factor-cleaving protease (“hvWF-cp”) or fragments thereof as affinity ligands. The adsorbents can be used for treating disorders associated with the occurrence of anti-vWF-cp-abs in patients,... Agent: Baxter Healthcare Corporation

20090264630 - Method of separating monomeric protein(s): The present invention relates to a method of separating one or more monomeric proteins, such as monomeric antibodies, from a liquid. The method comprises providing a thiophilic aromatic chromatography matrix; contacting the liquid that comprises proteins with the matrix; and recovering at least one monomeric protein, such as a monomeric... Agent: Ge Healthcare Bio-sciences Corp. Patent Department

20090264632 - Device and a method for promoting crystallisation: The invention relates to a microfluidic device for promoting crystallisation of target molecules, such as proteins. The device comprises a solid structure with a top face and an opposite bottom face and with a least one liquid channel. The liquid channel comprises a target molecule solution inlet and at least... Agent: Buchanan, Ingersoll & Rooney PC

20090259018 - Protein consentrate from starch containing grains: composition, method of making, and uses thereof: The present invention relates to methods of producing a protein concentrate from a starch containing grain and uses thereof. In an exemplary embodiment, the protein concentrate produced is used to prepare an aquaculture feed.... Agent: Usda-ars-office Of Technology Transfer Patent Advisors Office

20090259019 - Masp-2, a complement fixing enzyme, and uses for it: The invention relates to the discovery and characterization of mannan binding lectin-associated serine protease-2 (MASP-2), a new serine protease that acts in the MBLectin complement fixation pathway.... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20090259020 - Highly fluorinated beta-amino acids and methods of making and using same: wherein R1a and R1b are independently H, alkyl, F, or fluoroalkyl; wherein R2a, R2b, R2a′, and R2b′ are independently H, alkyl, F, fluoroalkyl, aryl, or alkenyl; wherein R3 is OH, alkoxyl, NH2, alkylamino, or dialkylamino; wherein R4a and R4b are independently H, alkyl, acyl, or alkyloxycarbonyl; wherein R11, R12, R13,... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20090259021 - Liquid phase peptide synthesis of kl-4 pulmonary surfactant: The invention relates to improved liquid phase processes for the preparation of the 21 residue protein component, (Lys-Leu4)4-Lys, of the pulmonary surfactant KL-4. These process are amenable to large scale synthesis and one process employs a method of saponifying an ester which reduces the inherent racemization of the α-carbon.... Agent: Philip S. Johnson Johnson & Johnson

20090259022 - Cdna encoding the human alpha2 delta4 calcium channel subunit: The present invention provides nucleic acid and polypeptide sequences describing an isoform of the α2δ-4 subunit of a voltage gated calcium channel. The nucleic acids described herein can be used to produce functional α2δ-4 protein. The calcium channel α2δ-4 protein may be isolated for the purposes of binding experiments or... Agent: Philip S. Johnson Johnson & Johnson

20090259024 - Glucose dehydrogenase from aspergillus oryzae: The present invention effectively produces glucose dehydrogenase derived from Aspergillus oryzae, and provides more practical glucose dehydrogenase. The invention makes it possible to efficiently produce glucose dehydrogenase and to obtain glucose dehydrogenase in more practical manner by using a glucose dehydrogenase gene isolated from Aspergillus oryzae.... Agent: Leydig Voit & Mayer, Ltd

20090259025 - Lactoferrin: A pure lactoferrin polypeptide containing no more than two metal ions per molecule, or a mixture of the polypeptide and a fragment thereof. The polypeptide or the mixture stimulates skeletal growth and inhibits bone resorption. Also disclosed is a method of treating a bone-related disorder with the polypeptide or the... Agent: Fish & Richardson PC

20090259023 - Liquid buffered gdf-5 formulations: Improved formulations and methods are provided for stabilizing a solution of bone morphogenetic protein. The compositions comprise an acetate buffered solution of GDF-5 and other excipients wherein the solution has a pH of from about 4.2 to about 5.3, thereby providing for a biologically isotonic solution having improved stability of... Agent: Philip S. Johnson Johnson & Johnson

20090259026 - Ligand: The invention provides a dual-specific ligand comprising a first immunoglobulin variable domain having a first binding specificity and a complementary or non-complementary immunoglobulin variable domain having a second binding specificity.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090259027 - Human gm-csf antibodies: Chimeric antibodies, as well as fusion proteins which comprise chimeric antibodies, are disclosed. The antibodies bind to GM-CSF, CD-30, and G250 antigen. The fusion proteins include biologically active portions of tumor necrosis factor, or full length tumor necrosis factor. Expression vectors adapted for production of the antibodies, as well as... Agent: Fulbright & Jaworski, LLP

20090259028 - Prevention of leaching of ligands from affinity-based purification systems: In an affinity-type purification, ligands dissociated from the stationary phase that would otherwise leach into the species being purified are captured by a second ligand that is also incorporated into the stationary phase, the second ligand exhibiting an affinity-type interaction with the dissociated first ligand with sufficient specificity to avoid... Agent: Townsend And Townsend And Crew, LLP

20090259029 - [1, 2, 4] triazolo [1, 5-a] pyrimidine derivatives as chromatographic adsorbent for the selective adsorption of igg: and its corresponding enol-form, wherein X represents O, S, or NH; R1 represents H, C1-6 alkyl, C1-6 alkoxy, C1-6 alkoxy-C1-6 alkyl, Ar, —C(O)NHR3, —C(O)—R3 or halo; R2 represents H, C1-3 alkyl or halo; R3 represents H, C1-6 alkyl, C1-6 alkoxy, C1-6 alkoxy-C1-6 alkyl or Ar; n represents 0, 1, 2... Agent: Ge Healthcare Bio-sciences Corp. Patent Department

20090253894 - Method of polymyxin b recovery from fermentation broth: The invention is related to the method of polymyxine B recovery from fermentation broth for the purpose of pure substance recovery. The invention mentioned above is obtained by using the method of polymyxine B recovery from fermentation broth according invention, which abstract is characterized by, that the filtrate is obtained... Agent: Michael Best & Friedrich LLP

20090253895 - Printable materials: The present invention provides compounds of the general formula I, and uses thereof for printing electronic components such as wires, resistors and LEDs.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090253896 - Selective substrates for matrix metalloproteinases: The invention provides isolated MMP-2, MMP-9 and MT1-MMP selective substrate polypeptides or functional peptidomimetics. The selective substrate polypeptides contain the following sequences: MMP-2 selective substrate polypeptides contain SEQ ID NOS:1-27, MMP-9 selective substrate polypeptides contain SEQ ID NOS:28-35, and MT1-MMP selective substrate polypeptide contain SEQ ID NOS:36-40. In addition, the... Agent: Mcdermott, Will & Emery

20090253897 - Structural protein of adeno-associated virus with modified antigenicity, its production and its use: The present invention relates to a structural protein of adeno-associated virus (AAV) which comprises at least one modification which brings about a reduction in the antigenicity, its production and use.... Agent: Clark & Elbing LLP

20090253898 - Mathematical design of ion channel selectivity via inverse problem technology: Determining the structure of permanent charge for an ion channel formulates an abstract operator, describing ion channel parameters, comprising equations that are ill-posed. The model of ion channel behavior relates the function of the ion channel to the structure of permanent charge within the ion channel and concentrations ions around... Agent: Husch Blackwell Sanders, LLP Husch Blackwell Sanders LLP Welsh & Katz

20090253899 - Reconstituted polypeptides: The present invention provides modified fibronectin type III (Fn3) molecules, and nucleic acid molecules encoding the modified Fn3 molecules. Also provided are methods of preparing these molecules, and kits to perform the methods.... Agent: Viksnins Harris & Padys Pllp

20090253900 - Processing of peptides and proteins: The invention provides novel methionine aminopeptidase enzymes and their use.... Agent: Novo Nordisk, Inc. Intellectual Property Department